HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up

Christian Jackisch*, Roberto Hegg, Daniil Stroyakovskiy, Jin Seok Ahn, Bohuslav Melichar, Shin Cheh Chen, Sung Bae Kim, Mikhail Lichinitser, Elzbieta Starosławska, Georg Kunz, Silvia Falcon, Shou Tung Chen, Aulde Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

62 Scopus citations

Abstract

Background In the phase III, open-label, randomised HannaH study, fixed-dose neoadjuvant-adjuvant subcutaneous trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer was non-inferior to standard weight-based intravenous infusion in terms of serum trough concentration and pathological complete response (PCR). Evidence suggests that PCR, particularly total PCR (tPCR), is likely to predict clinical benefit. We report associations between tPCR and event-free survival (EFS) from HannaH (the largest population from a single study of patients presenting with newly diagnosed HER2-positive breast cancer treated with neoadjuvant-adjuvant trastuzumab to date) plus long-term efficacy and safety. Methods Eligible patients received four cycles of neoadjuvant docetaxel followed by four cycles of fluorouracil/epirubicin/cyclophosphamide administered concurrently with 3-weekly subcutaneous (600 mg fixed dose) or intravenous trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses). Post-surgery, patients received adjuvant trastuzumab as randomised to complete 1 year of standard treatment. In exploratory analyses, we used Cox regression to assess associations between tPCR and EFS. EFS rates per subgroup were estimated using the Kaplan-Meier method. Findings Three-year EFS rates were 76% for subcutaneous and 73% for intravenous trastuzumab (unstratified hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.69-1.30; intention-to-treat population). Three-year overall survival rates were 92% for subcutaneous and 90% for intravenous trastuzumab (unstratified HR 0.76, 95% CI 0.44-1.32). tPCR was associated with a reduced risk of an EFS event: subcutaneous arm HR 0.38 (95% CI 0.22-0.65); intravenous arm HR 0.32 (95% CI 0.18-0.60). Results were similar for subgroups, including oestrogen receptor status. The few additional adverse events occurring during treatment-free follow-up were balanced between arms. Interpretation Long-term efficacy supports the established non-inferiority of subcutaneous trastuzumab, and its safety profile remains consistent with the known intravenous profile. In each of HannaH's treatment arms, tPCR was associated with improved EFS, adding to evidence that tPCR is associated with clinical benefit in HER2-positive early breast cancer.

Original languageEnglish
Pages (from-to)62-75
Number of pages14
JournalEuropean Journal of Cancer
Volume62
DOIs
StatePublished - 01 07 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 The Author(s). Published by Elsevier Ltd.

Keywords

  • Herceptin
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Subcutaneous
  • Trastuzumab

Fingerprint

Dive into the research topics of 'HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up'. Together they form a unique fingerprint.

Cite this